Silence Therapeutics (SLN)
2.89
0.47 (19.42%)
At close: Apr 02, 2025, 3:59 PM
19.42% (1D)
| Bid | 2.3 |
| Market Cap | 136.48M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -0.99 |
| PE Ratio (ttm) | -2.92 |
| Forward PE | -10.71 |
| Analyst | Buy |
| Ask | 3.37 |
| Volume | 257,524 |
| Avg. Volume (20D) | 283,998 |
| Open | 2.45 |
| Previous Close | 2.42 |
| Day's Range | 2.41 - 2.90 |
| 52-Week Range | 2.37 - 24.38 |
| Beta | 1.07 |
About SLN
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 8, 2020
Employees 116
Stock Exchange NASDAQ
Ticker Symbol SLN
Analyst Forecast
According to 5 analyst ratings, the average rating for SLN stock is "Buy." The 12-month stock price forecast is $45, which is an increase of 1457.09% from the latest price.
Stock Forecasts1 month ago
-15.45%
Silence Therapeutics shares are trading lower afte...
Unlock content with
Pro Subscription
